Gilead Sciences 4Q Revenues: $2.2 billion (+10%) 4Q Earnings: $665.1 million (+6%) FY Revenues: $8.4 billion (+5%) FY Earnings: $2.8 billion (-3%) Comments: Antiviral product sales were up 9% to $1.9 billion in the quarter and up 8% to $7.1 billion for the year. Sales of Atripla were $863.3 million in the quarter (+11%) and $3.2 billion for the year (+10%). Sales of Truvada were $746.0 million in the quarter (+9%) and $2.9 billion for the year (+8%). Sales of Viread were flat at $190.9 mill...